SWEEP
25.5.2023 00:02:32 CEST | Business Wire | Press release
Sweep, the leading carbon and ESG management platform, today launched Sweep for Compliance, the first solution for reliable, transparent, and audit-ready reporting in compliance with the EU’s new Corporate Sustainability Reporting Directive (CSRD).
By 2025, an estimated 50,000 European Union businesses and at least 10,000 EU-based foreign companies will be falling under the scope of the CSRD, requiring them to communicate their 2024 extra-financial information. Globally, a rising number of sustainability disclosure regulations demand companies and financial institutions to track and publicly communicate new sets of data. If companies fail to act, they face compliance risks, such as financial sanctions, legal penalties, and damaging greenwashing accusations.
But, measuring ESG and carbon data is complex and time consuming without the right technology. Two-thirds (65%) of French business leaders believe their organization is not sufficiently prepared to meet ESG objectives, nor to fulfill regulatory requirements according to Workiva. Sweep for Compliance helps businesses easily comply with the right ESG, carbon, and regulatory disclosure requirements using advanced data analytics and reporting requirements directly embedded into the platform.
“In 2023, data collection can’t be a bottleneck for companies to track and improve their positive impact. Monitoring extra financial data is now a crucial business issue as European sustainability regulations become more stringent. Sweep for Compliance gives CFOs, CSOs, and auditors the most advanced tools to measure carbon and ESG data and comply with upcoming legislation,” says Rachel Delacour, CEO and Cofounder at Sweep.
Sweep for Compliance streamlines the disclosure exercise, from data gathering and quality checks, traceability and monitoring, to generating insights and in-depth reports. With up to 50% time saved in the auditing process, it ensures consistent, verified, and compliant ESG and carbon data reporting in one click. It’s the only solution on the market to help companies get ready and stay on track with disclosure requirements.
“With the growing number of sustainability regulations and stakeholder demands for transparency, companies are under pressure to accurately communicate their impact. By working with tech partners like Sweep, large organizations can streamline the collection, monitoring, and reporting of their non financial data in one single place,” says Jérémie Joos, Co-Head of ESG Center of Excellence at KPMG France.
Sweep is the trusted data partner for companies such as pet food giant Royal Canin and global leader in connected health company Withings. After launching Sweep for Supply Chain in February 2023, the company is committed to creating the best solutions for organizations to improve their ESG and carbon impact while avoiding non-compliance damages. That’s how they can lead – and thrive – in the future low carbon economy.
• • •
About Sweep
Sweep helps businesses track and act on their carbon and ESG data, so they can become Forever Companies.
The data-driven platform makes it easy to understand, manage, and report carbon emissions and ESG metrics. Powerful collaboration features and user-focused design empower staff and entire value chains to grow a sustainable business. And with all the data in one place, its advanced analytics offer comprehensive insights and deliver auditable reports aligned with the latest sustainability regulations and frameworks.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition, France Invest, and The International Emissions Trading Association. It was selected to join FrenchTech Next 120/40 program and was named “Europe’s fastest growing scale up by Financial Times’ Sifted.
For more information, visit sweep.net
About KPMG France
KPMG in France – market leader in Audit and Consulting – is a 11,000-strong team of professionals dedicated to creating a new prosperity that's set to enhance companies of all sizes. In 2022, a century after its founding, KPMG became a "société à mission” (Purpose-driven company). Its purpose is to work and innovate with passion, to build trust, to combine performance and responsibility and to develop talent at the heart of the economy, territories and society. Thanks to its multidisciplinary model, KPMG combines industry, ESG and digital expertise by relying on its ESG Center of Excellence and its community of 1 000 digital experts to support the growth and transformation projects of its 100,000 clients all over the country.
For more information, visit kpmg.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
